Shares of small biotech Instil Bio (TIL) have surged more than six times in market value in the past week. The upside came after rival Summit Therapeutics (SMMT) reported encouraging data from a late-stage study on its experimental bispecific antibody ivonescimab in certain patients with non-small cell lung cancer (NSCLC). SMMT's Drug Shows Meaningful Benefit Over MRK's Keytruda The phase III HARMONi-2 study compared ivonescimab with Merck's (MRK) blockbuster drug Keytruda (pembrolizumab) in patients with l ...